A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for a minimum of 120 weeks. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Epistemonikos ID: befc923866c49cf217593916d5121b7089c2bf06
First added on: Jul 17, 2025